Evidence map›Paper›PMID 17981772›Full record

ReviewFrontiers in bioscience : a journal and virtual library2008

Cftr gene targeting in mouse embryonic stem cells mediated by Small Fragment Homologous Replacement (SFHR).

Federica Sangiuolo, Maria Lucia Scaldaferri, Antonio Filareto, Paola Spitalieri, Lorenzo Guerra, Maria Favia, Rosa Caroppo, Ruggiero Mango, Emanuela Bruscia, Dieter C Gruenert and 3 more

Open access · bronzeAbstract readReview
In one paragraph

Review in Frontiers in bioscience : a journal and virtual library, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. CRISPR for cystic fibrosis: Advances and insights from a systematic review.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Federica SangiuoloDepartment of Biopathology and Diagnostic Imaging, Tor Vergata University, Rome, Italy. sangiuolo@med.uniroma2.it
Maria Lucia Scaldaferri
Antonio Filareto
Paola Spitalieri
Lorenzo Guerra
Maria Favia
Rosa Caroppo
Ruggiero Mango
Emanuela Bruscia
Dieter C Gruenert
Valeria Casavola
Massimo De Felici
Giuseppe Novelli
University of Rome Tor Vergata · IT

Funding

Generation of a CF Pig by SFHR and Nuclear TransferR21DK066403 · NIDDK · CALIFORNIA PACIFIC MED CTR RES INSTITUTE · PI GRUENERT, DIETER C · 2004 to 2005
$320k
Development of a Genetic Therapy for CF in a CF RabbitR41HL080814 · NHLBI · EVERGEN BIOTECHNOLOGIES, INC. · PI GRUENERT, DIETER C · 2005 to 2005
$140k
NHLBI NIH HHS HL80814NHLBI NIH HHS R41 HL080814NIDDK NIH HHS DK066403NIDDK NIH HHS R21 DK066403
6 · The paper itself

Abstract

Different gene targeting approaches have been developed to modify endogenous genomic DNA in both human and mouse cells. Briefly, the process involves the targeting of a specific mutation in situ leading to the gene correction and the restoration of a normal gene function. Most of these protocols with therapeutic potential are oligonucleotide based, and rely on endogenous enzymatic pathways. One gene targeting approach, "Small Fragment Homologous Replacement (SFHR)", has been found to be effective in modifying genomic DNA. This approach uses small DNA fragments (SDF) to target specific genomic loci and induce sequence and subsequent phenotypic alterations. This study shows that SFHR can stably introduce a 3-bp deletion (deltaF508, the most frequent cystic fibrosis (CF) mutation) into the Cftr (CF Transmembrane Conductance Regulator) locus in the mouse embryonic stem (ES) cell genome. After transfection of deltaF508-SDF into murine ES cells, SFHR-mediated modification was evaluated at the molecular levels on DNA and mRNA obtained from transfected ES cells. About 12% of transcript corresponding to deleted allele was detected, while 60% of the electroporated cells completely lost any measurable CFTR-dependent chloride efflux. The data indicate that the SFHR technique can be used to effectively target and modify genomic sequences in ES cells. Once the SFHR-modified ES cells differentiate into different cell lineages they can be useful for elucidating tissue-specific gene function and for the development of transplantation-based cellular and therapeutic protocols.

Indexed as

AnimalsCloning, MolecularCystic Fibrosis Transmembrane Conductance RegulatorDNAEmbryonic Stem CellsGene TargetingGenetic TechniquesMiceMicroscopy, FluorescenceMicroscopy, VideoMotor NeuronsMutationReverse Transcriptase Polymerase Chain ReactionRNAStem CellsCystic Fibrosis Transmembrane Conductance RegulatorDNARNA

Identifiers

PMID17981772
PMCPMC3725395
OpenAlexW2125003065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.